JP7432532B2 - Ｔ細胞アクティベーターとして有用な置換ナフチリジノン化合物 - Google Patents

Ｔ細胞アクティベーターとして有用な置換ナフチリジノン化合物 Download PDF

Info

Publication number
JP7432532B2
JP7432532B2 JP2020572691A JP2020572691A JP7432532B2 JP 7432532 B2 JP7432532 B2 JP 7432532B2 JP 2020572691 A JP2020572691 A JP 2020572691A JP 2020572691 A JP2020572691 A JP 2020572691A JP 7432532 B2 JP7432532 B2 JP 7432532B2
Authority
JP
Japan
Prior art keywords
methyl
dihydro
oxo
naphthyridine
carbonitrile
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
JP2020572691A
Other languages
English (en)
Japanese (ja)
Other versions
JP2021529191A5 (https=
JPWO2020006018A5 (https=
JP2021529191A (ja
Inventor
アッペンダー・ベラパルチ
ルイス・エス・チュパック
チェタン・パドマカル・ダルネ
ミン・ディン
ロバート・ジー・ジェントルズ
ヤージョン・フアン
マンジュナタ・ナラヤナ・ラオ・カンブレ
スコット・ダブリュー・マーティン
ラジュ・マヌーリ
アイバー・エム・マクドナルド
リチャード・イー・オルソン
ハシブル・ラーマン
プラサダ・ラオ・ジャラガム
ソーミャ・ロイ
ゴピキシャン・トヌクヌル
シヴァスダル・ヴェライアー
ジャヤクマール・サンカラ・ウォリアー
シャオファン・ジェン
ジョン・エス・トカルスキー
ビレシュワル・ダスグプタ
コタ・ラトナカル・レディ
ティルベンカダム・ラジャ
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Bristol Myers Squibb Co
Original Assignee
Bristol Myers Squibb Co
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Bristol Myers Squibb Co filed Critical Bristol Myers Squibb Co
Publication of JP2021529191A publication Critical patent/JP2021529191A/ja
Publication of JP2021529191A5 publication Critical patent/JP2021529191A5/ja
Publication of JPWO2020006018A5 publication Critical patent/JPWO2020006018A5/ja
Application granted granted Critical
Publication of JP7432532B2 publication Critical patent/JP7432532B2/ja
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/04—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/496—Non-condensed piperazines containing further heterocyclic rings, e.g. rifampin, thiothixene or sparfloxacin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Epidemiology (AREA)
  • Virology (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
  • Peptides Or Proteins (AREA)
JP2020572691A 2018-06-27 2019-06-26 Ｔ細胞アクティベーターとして有用な置換ナフチリジノン化合物 Active JP7432532B2 (ja)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US201862690439P 2018-06-27 2018-06-27
US62/690,439 2018-06-27
US201962840459P 2019-04-30 2019-04-30
US62/840,459 2019-04-30
PCT/US2019/039135 WO2020006018A1 (en) 2018-06-27 2019-06-26 Substituted naphthyridinone compounds useful as t cell activators

Publications (4)

Publication Number Publication Date
JP2021529191A JP2021529191A (ja) 2021-10-28
JP2021529191A5 JP2021529191A5 (https=) 2022-07-04
JPWO2020006018A5 JPWO2020006018A5 (https=) 2022-07-04
JP7432532B2 true JP7432532B2 (ja) 2024-02-16

Family

ID=67439335

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2020572691A Active JP7432532B2 (ja) 2018-06-27 2019-06-26 Ｔ細胞アクティベーターとして有用な置換ナフチリジノン化合物

Country Status (28)

Country Link
US (3) US10669272B2 (https=)
EP (1) EP3814348B9 (https=)
JP (1) JP7432532B2 (https=)
KR (1) KR102767739B1 (https=)
CN (1) CN112654621B (https=)
AU (1) AU2019291794B2 (https=)
BR (1) BR112020026681A2 (https=)
CA (1) CA3104654A1 (https=)
CL (1) CL2020003260A1 (https=)
CY (1) CY1126280T1 (https=)
DK (1) DK3814348T3 (https=)
ES (1) ES2960754T3 (https=)
FI (1) FI3814348T3 (https=)
HR (1) HRP20231253T1 (https=)
HU (1) HUE064531T2 (https=)
IL (1) IL279728B2 (https=)
LT (1) LT3814348T (https=)
MX (1) MX2020013817A (https=)
PE (1) PE20210469A1 (https=)
PL (1) PL3814348T3 (https=)
PT (1) PT3814348T (https=)
RS (1) RS64641B1 (https=)
SG (1) SG11202012972YA (https=)
SI (1) SI3814348T1 (https=)
SM (1) SMT202300466T1 (https=)
TW (1) TW202019924A (https=)
WO (1) WO2020006018A1 (https=)
ZA (1) ZA202100555B (https=)

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2023510108A (ja) * 2019-12-19 2023-03-13 ブリストル－マイヤーズ スクイブ カンパニー Ｄｇｋ阻害剤およびチェックポイントアンタゴニストの組み合わせ

Families Citing this family (37)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN111471059B (zh) * 2019-01-23 2022-12-02 药捷安康(南京)科技股份有限公司 Pde9抑制剂及其用途
AU2020266529B2 (en) 2019-04-29 2026-01-29 Solent Therapeutics, Llc 3-amino-4H-benzo[E][1,2,4]thiadiazine 1,1-dioxide derivatives as inhibitors of MRGX2
AR119821A1 (es) 2019-08-28 2022-01-12 Bristol Myers Squibb Co Compuestos de piridopirimidinonilo sustituidos útiles como activadores de células t
CN115210225A (zh) 2019-11-28 2022-10-18 拜耳公司 取代的氨基喹诺酮类作为免疫激活的dgkalpha抑制剂
US20230064809A1 (en) 2019-11-28 2023-03-02 Bayer Aktiengesellschaft Substituted aminoquinolones as dgkalpha inhibitors for immune activation
KR20220122637A (ko) 2019-11-28 2022-09-02 바이엘 악티엔게젤샤프트 면역 활성화를 위한 dgk알파 억제제로서의 치환된 아미노퀴놀론
KR20220119456A (ko) * 2019-12-23 2022-08-29 브리스톨-마이어스 스큅 컴퍼니 T 세포 활성화제로서 유용한 치환된 퀴놀리노닐 피페라진 화합물
AR120823A1 (es) * 2019-12-23 2022-03-23 Bristol Myers Squibb Co Compuestos bicíclicos sustituidos útiles como activadores de células t
IL294273A (en) * 2019-12-23 2022-08-01 Bristol Myers Squibb Co Substituted heteroaryl compounds are useful as t-cell activators
EP4081522A1 (en) * 2019-12-23 2022-11-02 Bristol-Myers Squibb Company Substituted piperazine derivatives useful as t cell activators
CN114846007B (zh) 2019-12-23 2024-11-22 百时美施贵宝公司 可用作t细胞激活剂的经取代的喹唑啉基化合物
LT4081305T (lt) 2019-12-24 2024-11-25 Carna Biosciences, Inc. Diacilglicerolio kinazę moduliuojantys junginiai
AR120896A1 (es) * 2019-12-25 2022-03-30 Astellas Pharma Inc COMPUESTO DE PIRIDAZINIL-TIAZOLCARBOXAMIDA COMO INHIBIDORES DE DGKz
PL4139286T3 (pl) 2020-04-24 2025-08-11 Bayer Aktiengesellschaft Podstawione aminotiazole jako inhibitory dgkzeta do aktywacji immunologicznej
WO2021258010A1 (en) * 2020-06-19 2021-12-23 Gossamer Bio Services, Inc. Oxime compounds useful as t cell activators
CN116615199A (zh) * 2020-11-26 2023-08-18 株式会社Lg化学 作为二酰基甘油激酶抑制剂的杂环化合物及其用途
AR124172A1 (es) * 2020-11-30 2023-02-22 Astellas Pharma Inc Compuesto de heteroarilcarboxamida
EP4262986A1 (en) 2020-12-16 2023-10-25 Gossamer Bio Services, Inc. Compounds useful as t cell activators
JP2024509853A (ja) 2021-03-03 2024-03-05 ジュノー セラピューティクス インコーポレイテッド Ｔ細胞療法およびｄｇｋ阻害剤の組合せ
WO2022271659A1 (en) 2021-06-23 2022-12-29 Gilead Sciences, Inc. Diacylglyercol kinase modulating compounds
WO2022271677A1 (en) 2021-06-23 2022-12-29 Gilead Sciences, Inc. Diacylglyercol kinase modulating compounds
CA3222277A1 (en) 2021-06-23 2022-12-29 Gilead Sciences, Inc. Diacylglyercol kinase modulating compounds
KR20240005901A (ko) 2021-06-23 2024-01-12 길리애드 사이언시즈, 인코포레이티드 디아실글리세롤 키나제 조절 화합물
WO2023122777A1 (en) * 2021-12-22 2023-06-29 Gossamer Bio Services, Inc. Oxime derivatives useful as t cell activators
EP4472963A1 (en) * 2022-02-01 2024-12-11 Arvinas Operations, Inc. Dgk targeting compounds and uses thereof
WO2023165525A1 (en) * 2022-03-01 2023-09-07 Insilico Medicine Ip Limited Diacylglycerol kinase (dgk) alpha inhibitors and uses thereof
KR20240156394A (ko) 2022-03-01 2024-10-29 인실리코 메디신 아이피 리미티드 디아실글리세롤 키나아제 (dgk) 알파 억제제 및 이의 용도
CN118829642A (zh) * 2022-03-01 2024-10-22 英矽智能科技知识产权有限公司 二酰基甘油激酶(DGK)α抑制剂及其用途
KR20240161147A (ko) 2022-03-14 2024-11-12 슬랩 파마슈티컬스 엘엘씨 다중 사이클릭 화합물
WO2023184327A1 (en) * 2022-03-31 2023-10-05 InventisBio Co., Ltd. Kinase inhibitors, preparation methods and uses thereof
US12600723B2 (en) 2022-07-18 2026-04-14 Incyte Corporation Tetracyclic compounds as DGK inhibitors
US12600722B2 (en) 2022-07-18 2026-04-14 Incyte Corporation Tetracyclic compounds as DGK inhibitors
US20240083898A1 (en) * 2022-08-15 2024-03-14 Incyte Corporation Tricyclic triazolo compounds as dgk inhibitors
CN120152717A (zh) 2022-09-08 2025-06-13 朱诺治疗学股份有限公司 T细胞疗法和连续或间歇dgk抑制剂给药的组合
AR131786A1 (es) 2023-02-06 2025-04-30 Bayer Ag Combinación de anticuerpos ccr8 con inhibidores de dgk
CN116375654B (zh) * 2023-03-22 2024-12-31 湖北三峡实验室 一种由双甘肽制备2,5-二酮哌嗪的方法
CN119143715B (zh) * 2024-11-12 2025-03-14 天津匠新致成科技有限公司 二芳基团甲基哌嗪类化合物及其制备方法、药物组合物和应用

Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20050266510A1 (en) 2004-01-08 2005-12-01 Gajewski Thomas G T cell anergy is reversed by active Ras and regulated by diacylglycerol kinase
JP2007503388A (ja) 2003-08-22 2007-02-22 アバニール・ファーマシューティカルズ マクロファージ遊走阻止因子の阻害剤としての置換ナフチリジン誘導体、およびヒト疾患の治療におけるそれらの使用
JP2009530384A (ja) 2006-03-21 2009-08-27 アヴァニール ファーマシューティカルズ 腫瘍壊死因子アルファ阻害（抑制）剤及びそれらのヒトの病気処理における使用
WO2017177037A1 (en) 2016-04-06 2017-10-12 University Of Virginia Patent Foundation Compositions and methods for treating cancer

Family Cites Families (63)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4324893A (en) 1979-04-18 1982-04-13 American Home Products Corporation 4-Amino-3-carboxy or cyano-1,2-dihydro-2-oxo-1,8-naphthyridine derivatives
MY140679A (en) 2001-05-24 2010-01-15 Avanir Pharmaceuticals Inhibitors of macrohage migration inhibitory factor and methods for identifying the same
WO2004002960A1 (en) 2002-06-27 2004-01-08 Schering Aktiengesellschaft Substituted quinoline ccr5 receptor antagonists
GB0230018D0 (en) 2002-12-23 2003-01-29 Syngenta Ltd Fungicides
TW200418829A (en) 2003-02-14 2004-10-01 Avanir Pharmaceutics Inhibitors of macrophage migration inhibitory factor and methods for identifying the same
JP2006521400A (ja) 2003-03-26 2006-09-21 バイエル・フアーマシユーチカルズ・コーポレーシヨン 糖尿病及び関連障害の処置のための化合物及びそれらの使用
GB0316915D0 (en) 2003-07-18 2003-08-20 Glaxo Group Ltd Compounds
AU2004259755A1 (en) 2003-07-22 2005-02-03 Janssen Pharmaceutica, N.V. Quinolinone derivatives as inhibitors of c-fms kinase
TWI309240B (en) 2004-09-17 2009-05-01 Hoffmann La Roche Anti-ox40l antibodies
AU2006230099B2 (en) 2005-03-25 2012-04-19 Gitr, Inc. GITR binding molecules and uses therefor
PL1879573T3 (pl) 2005-05-10 2013-05-31 Incyte Holdings Corp Modulatory 2,3-dioksygenazy indoloaminy i sposoby ich zastosowania
CN104356236B (zh) 2005-07-01 2020-07-03 E.R.施贵宝&圣斯有限责任公司 抗程序性死亡配体1(pd-l1)的人单克隆抗体
CA2634198C (en) 2005-12-20 2014-06-03 Incyte Corporation N-hydroxyamidinoheterocycles as modulators of indoleamine 2,3-dioxygenase
JP2007308402A (ja) 2006-05-17 2007-11-29 Sumitomo Chemical Co Ltd シンナモイル化合物及びその用途
JP2007308441A (ja) 2006-05-22 2007-11-29 Sumitomo Chemical Co Ltd 含複素環化合物及びその用途
ES2444574T3 (es) 2006-09-19 2014-02-25 Incyte Corporation N-hidroxiamidinoheterociclos como moduladores de la indolamina 2,3-dioxigenasa
CL2007002650A1 (es) 2006-09-19 2008-02-08 Incyte Corp Compuestos derivados de heterociclo n-hidroxiamino; composicion farmaceutica, util para tratar cancer, infecciones virales y desordenes neurodegenerativos entre otras.
EP1987839A1 (en) 2007-04-30 2008-11-05 I.N.S.E.R.M. Institut National de la Sante et de la Recherche Medicale Cytotoxic anti-LAG-3 monoclonal antibody and its use in the treatment or prevention of organ transplant rejection and autoimmune disease
ES2776406T3 (es) 2007-07-12 2020-07-30 Gitr Inc Terapias de combinación que emplean moléculas de enlazamiento a GITR
EP2044949A1 (en) 2007-10-05 2009-04-08 Immutep Use of recombinant lag-3 or the derivatives thereof for eliciting monocyte immune response
JP5583592B2 (ja) 2007-11-30 2014-09-03 ニューリンク ジェネティクス コーポレイション Ｉｄｏ阻害剤
US20110176972A1 (en) 2008-05-29 2011-07-21 Saint-Gobain Centre De Recherches et D'Etudes Eur Cellular structure containing aluminium titanate
AR072999A1 (es) 2008-08-11 2010-10-06 Medarex Inc Anticuerpos humanos que se unen al gen 3 de activacion linfocitaria (lag-3) y los usos de estos
US20110281908A1 (en) 2008-10-06 2011-11-17 Emory University Aminoquinoline Derived Heat Shock Protein 90 Inhibitors, Methods Of Preparing Same, And Methods For Their Use
AU2009333580B2 (en) 2008-12-09 2016-07-07 Genentech, Inc. Anti-PD-L1 antibodies and their use to enhance T-cell function
US20110319416A1 (en) 2009-01-28 2011-12-29 Emory University Subunit Selective NMDA Receptor Antagonists For The Treatment Of Neurological Conditions
EP2473531A4 (en) 2009-09-03 2013-05-01 Merck Sharp & Dohme Anti-gitr antibodies
US8722720B2 (en) 2009-10-28 2014-05-13 Newlink Genetics Corporation Imidazole derivatives as IDO inhibitors
PH12012500881A1 (en) 2009-12-10 2017-07-26 Hoffmann La Roche Antibodies binding preferentially human csf1r extracellular domain 4 and their use
JP5998060B2 (ja) 2010-03-04 2016-09-28 マクロジェニクス，インコーポレーテッド Ｂ７−ｈ３と反応性のある抗体、その免疫学的に活性なフラグメントおよびその使用
CA2789076C (en) 2010-03-05 2017-11-21 F. Hoffmann-La Roche Ag Antibodies against human colony stimulating factor-1 receptor and uses thereof
CN102918061B (zh) 2010-03-05 2016-06-08 霍夫曼-拉罗奇有限公司 针对人csf-1r的抗体及其用途
MX378336B (es) 2010-05-04 2025-03-10 Five Prime Therapeutics Inc Anticuerpos que se unen a factor estimulante de colonias 1 (csf1r).
EP2592933B1 (en) 2010-07-16 2017-04-05 Anderson Gaweco Mif inhibitors and their uses
PT2614082T (pt) 2010-09-09 2018-12-03 Pfizer Moléculas de ligação a 4-1bb
US9133164B2 (en) 2011-04-13 2015-09-15 Innov88 Llc MIF inhibitors and their uses
NO2694640T3 (https=) 2011-04-15 2018-03-17
KR101970025B1 (ko) 2011-04-20 2019-04-17 메디뮨 엘엘씨 Ｂ7-ｈ1 및 ｐｄ-1과 결합하는 항체 및 다른 분자들
HRP20201595T1 (hr) 2011-11-28 2020-12-11 Merck Patent Gmbh Anti-pd-l1 protutijela i njihova uporaba
BR112014012624A2 (pt) 2011-12-15 2018-10-09 F Hoffmann-La Roche Ag anticorpos, composição farmacêutica, ácido nucleico, vetores de expressão, célula hospedeira, método para a produção de um anticorpo recombinante e uso do anticorpo
RU2014136332A (ru) 2012-02-06 2016-03-27 Дженентек, Инк. Композиции и способы применения ингибиторов csf1r
WO2013118071A1 (en) 2012-02-09 2013-08-15 Glenmark Pharmaceuticals S.A. BICYCLIC COMPOUNDS AS mPGES-1 INHIBITORS
AR090263A1 (es) 2012-03-08 2014-10-29 Hoffmann La Roche Terapia combinada de anticuerpos contra el csf-1r humano y las utilizaciones de la misma
EP2847220A1 (en) 2012-05-11 2015-03-18 Five Prime Therapeutics, Inc. Methods of treating conditions with antibodies that bind colony stimulating factor 1 receptor (csf1r)
AR091649A1 (es) 2012-07-02 2015-02-18 Bristol Myers Squibb Co Optimizacion de anticuerpos que se fijan al gen de activacion de linfocitos 3 (lag-3) y sus usos
CN107759690A (zh) 2012-08-31 2018-03-06 戊瑞治疗有限公司 用结合群落刺激因子1受体(csf1r)的抗体治疗病状的方法
WO2014039513A2 (en) 2012-09-04 2014-03-13 The Trustees Of The University Of Pennsylvania Inhibition of diacylglycerol kinase to augment adoptive t cell transfer
JP2018513853A (ja) 2015-04-10 2018-05-31 アラクセス ファーマ エルエルシー 置換キナゾリン化合物およびその使用方法
CA3005766A1 (en) 2015-12-17 2017-06-22 Merck Patent Gmbh Polycyclic tlr7/8 antagonists and use thereof in the treatment of immune disorders
CN107216325B (zh) 2016-03-22 2019-06-25 上海医药工业研究院 萘啶酮类化合物、及其制备方法和应用
WO2018119183A2 (en) 2016-12-22 2018-06-28 Amgen Inc. Kras g12c inhibitors and methods of using the same
WO2018134885A1 (ja) 2017-01-17 2018-07-26 初実 田中 支援奨励システムおよび支援奨励方法
GB201700814D0 (en) 2017-01-17 2017-03-01 Liverpool School Tropical Medicine Compounds
EA201992781A1 (ru) 2017-05-22 2020-04-01 Эмджен Инк. Ингибиторы g12c kras и способы их применения
US12187687B2 (en) 2017-06-26 2025-01-07 University Of Virginia Patent Foundation Compositions and uses thereof
PL3761980T3 (pl) 2018-03-07 2024-06-10 Pliant Therapeutics, Inc. Związki aminokwasowe i sposoby zastosowania
US20210238136A1 (en) 2018-06-07 2021-08-05 Daiichi Sankyo Company, Limited Azetidine derivative, and prodrug thereof
CN112469707B (zh) 2018-06-27 2024-06-21 利伯纳生物科学株式会社 脊髓性肌萎缩症的预防剂或治疗剂
TWI841573B (zh) 2018-06-27 2024-05-11 美商普萊恩醫療公司 具有未分支連接子之胺基酸化合物及使用方法
BR112020026580A2 (pt) 2018-06-27 2021-03-23 Proteostasis Therapeutics, Inc. (Fem) Compostos, composição farmacêutica e métodos para tratar um paciente
MX2020013895A (es) 2018-06-27 2021-07-21 Biogen Ma Inc Agentes inhibidores de ask1.
MY204443A (en) 2018-06-27 2024-08-28 Oscotec Inc Pyridopyrimidinone derivatives for use as axl inhibitors
TWI833770B (zh) 2018-06-27 2024-03-01 美商Ionis製藥公司 用於減少 lrrk2 表現之化合物及方法

Patent Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2007503388A (ja) 2003-08-22 2007-02-22 アバニール・ファーマシューティカルズ マクロファージ遊走阻止因子の阻害剤としての置換ナフチリジン誘導体、およびヒト疾患の治療におけるそれらの使用
US20050266510A1 (en) 2004-01-08 2005-12-01 Gajewski Thomas G T cell anergy is reversed by active Ras and regulated by diacylglycerol kinase
JP2009530384A (ja) 2006-03-21 2009-08-27 アヴァニール ファーマシューティカルズ 腫瘍壊死因子アルファ阻害（抑制）剤及びそれらのヒトの病気処理における使用
WO2017177037A1 (en) 2016-04-06 2017-10-12 University Of Virginia Patent Foundation Compositions and methods for treating cancer

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2023510108A (ja) * 2019-12-19 2023-03-13 ブリストル－マイヤーズ スクイブ カンパニー Ｄｇｋ阻害剤およびチェックポイントアンタゴニストの組み合わせ

Also Published As

Publication number Publication date
PT3814348T (pt) 2023-10-17
BR112020026681A2 (pt) 2021-04-06
IL279728B2 (en) 2023-07-01
SMT202300466T1 (it) 2024-01-10
AU2019291794B2 (en) 2022-06-16
CL2020003260A1 (es) 2021-04-23
MX2020013817A (es) 2021-03-09
HRP20231253T1 (hr) 2024-02-02
RS64641B1 (sr) 2023-10-31
PL3814348T3 (pl) 2023-09-11
ES2960754T3 (es) 2024-03-06
US10669272B2 (en) 2020-06-02
DK3814348T3 (da) 2023-10-30
KR102767739B1 (ko) 2025-02-12
IL279728A (en) 2021-03-01
EP3814348B1 (en) 2023-08-02
AU2019291794A1 (en) 2021-02-11
PE20210469A1 (es) 2021-03-08
CN112654621B (zh) 2024-05-14
TW202019924A (zh) 2020-06-01
EP3814348A1 (en) 2021-05-05
LT3814348T (lt) 2023-10-10
CN112654621A (zh) 2021-04-13
SG11202012972YA (en) 2021-01-28
IL279728B1 (en) 2023-03-01
EP3814348B9 (en) 2023-11-01
US11713316B2 (en) 2023-08-01
HUE064531T2 (hu) 2024-04-28
US20200109140A1 (en) 2020-04-09
US20220324859A1 (en) 2022-10-13
CY1126280T1 (el) 2026-02-25
JP2021529191A (ja) 2021-10-28
FI3814348T3 (fi) 2023-09-22
WO2020006018A1 (en) 2020-01-02
SI3814348T1 (sl) 2023-10-30
CA3104654A1 (en) 2020-01-02
US10954238B1 (en) 2021-03-23
ZA202100555B (en) 2022-07-27
KR20210024586A (ko) 2021-03-05

Similar Documents

Publication Publication Date Title
JP7432532B2 (ja) Ｔ細胞アクティベーターとして有用な置換ナフチリジノン化合物
JP7650864B2 (ja) Ｔ細胞アクティベーターとして有用な置換ピリドピリミジノニル化合物
JP7373512B2 (ja) Ｔ細胞アクティベーターとして有用なナフチリジノン化合物
JP7653440B2 (ja) Ｔ細胞アクティベーターとして有用な置換二環化合物
JP7712274B2 (ja) Ｔ細胞アクティベーターとして有用な置換ピペラジン誘導体
WO2020023356A1 (en) Inhibitors of indoleamine 2,3-dioxygenase and methods of their use
JP7808733B2 (ja) 置換オキソイソインドリニルピペリジン－２，６－ジオン化合物
EA043061B1 (ru) Замещенные нафтиридиноновые соединения, полезные в качестве активаторов т-клеток
HK40069881A (zh) 抗病毒吡唑并吡啶酮化合物

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20220624

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20220624

A977 Report on retrieval

Free format text: JAPANESE INTERMEDIATE CODE: A971007

Effective date: 20230608

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20230627

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20230728

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20230912

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20231026

TRDD Decision of grant or rejection written
A01 Written decision to grant a patent or to grant a registration (utility model)

Free format text: JAPANESE INTERMEDIATE CODE: A01

Effective date: 20240109

A61 First payment of annual fees (during grant procedure)

Free format text: JAPANESE INTERMEDIATE CODE: A61

Effective date: 20240205

R150 Certificate of patent or registration of utility model

Ref document number: 7432532

Country of ref document: JP

Free format text: JAPANESE INTERMEDIATE CODE: R150